Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK, Impax Enter Parkinson’s Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

GSK, Impax Enter Parkinson’s Pact

GlaxoSmithKline and Impax Pharmaceuticals entered an agreement for the development and commercialization of IPX066, Impax’s extended release carbidopa-levodopa product, outside the U.S. and Taiwan.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and Impax Pharmaceuticals entered an agreement for the development and commercialization of IPX066, Impax’s extended release carbidopa-levodopa product, outside the U.S. and Taiwan. IPX066 is an investigational drug under development for the treatment of Parkinson’s Disease (PD), and is currently in Phase III trials.

GSK will have an exclusive license to sell IPX066 throughout the world except in the U.S. and Taiwan. Impax will receive $11.5 million upfront and is eligible to receive potential milestone payments of as much as $175 million upon successful development and commercialization. Impax will also receive royalty payments on GSK sales of the drug. Impax will manufacture and supply IPX066 to GSK.

Impax will complete its current Phase III program, with results expected in 2011. In the U.S., Impax plans to file a NDA for PD in late 2011 and will be responsible for commercialization. In other regions, excluding Taiwan, GSK will be responsible for further development, registration and commercialization of IPX066 in those markets.

“We are very pleased to announce this development and collaboration agreement with GSK, which is a significant milestone in the development of Impax Pharmaceuticals and an important achievement in the planned global commercialization for IPX066 for the treatment of Parkinson’s Disease,” said Michael Nestor, president of Impax Pharmaceuticals. “GSK is an ideal partner for IPX066, combining global best-in-class development, regulatory and commercial experience in Parkinson’s Disease, which will be an asset in the successful commercialization of IPX066.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters